APEIRON, LDC ink discovery deal
VIENNA—A new collaboration agreement is underway between APEIRON Biologics AG and the Lead Discovery Center (LDC) GmbH, a translational research organization established by Max Planck Innovation. The companies will seek to develop novel immune checkpoint modulators for oncology, collaborating on drug discovery activities to optimize and develop novel small-molecule candidates. Specific financial details were not disclosed, but APEIRON will hold rights to any molecules that result from this agreement. The LDC will receive research funding and also stands to receive an upfront payment, milestone payments and royalties. The research will be performed at APEIRON’s R&D sites in Vienna and at LDC’s Dortmund, Germany laboratories. APEIRON will assume responsibility for additional preclinical and clinical development, marketing and commercialization of any resulting candidates.